- Home
- Equipment
- usa california
- immunotherapy
Show results for
Refine by
Immunotherapy Equipment Supplied In Usa California
32 equipment items found
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated ...
Manufactured by:AIVITA Biomedical, Inc. based in, CALIFORNIA (USA)
AIVITA’s immunotherapy technology creates personalized vaccines for cancer patients that target and eliminate tumor-initiating cells which are the seed of the disease. Used alone or in parallel with other treatments, AIVITA’s cancer immunotherapy represents a powerful new approach in the search for curative treatments for ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento’s proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences. This makes it one of the largest fully human antibody libraries in the ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv ...
by:National Resilience, Inc. based inSan Diego, CALIFORNIA (USA)
Innovators in immunotherapy, stem cell therapy, and regenerative medicine will find like-minded champions at ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
648 gene panel + Whole transcriptome RNA sequencing with validated fusion detection, Enriched for clinically relevant genes and genes of emerging clinical relevance, Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB), IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, and 28-8 clones), Available Add-on Tests: Tumor Origin (TO), Homologous Recombination ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. We are developing FT573, an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master engineered iPSC line. FT573 incorporates four functional modifications: a proprietary CAR that targets B7H3; a ...
Manufactured by:Actym Therapeutics based inBerkeley, CALIFORNIA (USA)
Actym Therapeutics, based in Berkeley, CA, is a privately held biotechnology company focused on the discovery and development of novel immunotherapies to treat cancer. The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid ...
Manufactured by:Indee Labs based inBerkeley, CALIFORNIA (USA)
Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the power of microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene-editing complexes to immune ...
Manufactured by:MiraDx based inLos Angeles, CALIFORNIA (USA)
We are working with potential partners to incorporate these findings into the newer agents to allow better patients selection to achieve improved response and less toxicity from these exciting new therapies. We are additionally working with partners to apply these mutations to all classes of developing ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered iPSC lines as off-the-shelf cancer immunotherapies for the treatment of hematologic malignancies and solid ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
While most researchers and clinical investigators continue to focus on the development of autologous or donor-derived CAR T-cell therapies, we are developing CAR T-cell product candidates created from clonal master engineered iPSC lines as off-the-shelf cancer immunotherapies for the treatment of hematologic malignancies and solid tumors. ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
IRX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target. IRX-2 is produced under cGMP (current good manufacturing process) conditions following ...
Manufactured by:Ibio, Inc. based inBryan, TEXAS (USA)
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant challenges remain. This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and ...
by:LIXTE Biotechnology Holdings, Inc. based inPasadena, CALIFORNIA (USA)
In addition, given at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely used new immunotherapy ...
Manufactured by:Brooklyn ImmunoTherapeutics (BTX) based inSan Diego, CALIFORNIA (USA)
Utilizing highly efficient mRNA-based gene editing, Brooklyn will precisely engineer changes in the genome of iPSC, followed by a thorough characterization of the new cell line. The gene-edited iPSC will then be used to produce iMSC that have been endowed with beneficial properties to broaden and enhance therapeutic uses. Our first gene-edited iMSC product will be used as a cancer ...
by:Dorian Therapeutics based inSan Carlos, CALIFORNIA (USA)
During aging, there is a decrease in the activity of stem cells, and therefore a reduced regenerative capacity. Additionally, senescent cells accumulate in the body and poison entire tissues. Dorian’s Senoblockers act on epigenetic regulators to reverse both processes, reactivating programs of youthfulness and regeneration. ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-106, an antagonist antibody targeting LAIR1, an immune inhibitory receptor. The company’s preclinical research supports the proposed mechanisms of action of IO-106 and its evaluation as a potential treatment for solid ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting BCMA with CAR T cells. ...
Manufactured by:Immune-Onc Therapeutics, Inc. based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...